Yes, there are cheaper sticker prices out there, but those peptides are unlikely to be pure and are likely stuffed with fillers and additives
As demand outpaces supply, shortages have been reported, particularly in Europe, where the European Medicines Agency (EMA) does not anticipate resolution until beyond 2024
But thats all to say that clinicians would be certainly on a reasonable evidentiary base of practice
Studies have found that GLP-1 RAs have multiple beneficial effects in the cardiovascular system, including improving cardiovascular function and inhibiting the development and rupture of atherosclerotic plaques, and thus GLP-1 RAs may have cardiovascular protective potential, slightly reducing the risk of death due to cardiovascular disease and any cause, and slightly reducing the risk of stroke compared to placebo
Exposure to harmful chemicals further reduces our glutathione levels
When comparing patients with high-risk PFO to all controls, independent association was not found for any MET category
